LUNG CANCER

A phase 2 dose expansion cohort which received the investigational agent abequolixron plus docetaxel showed clinical responses in patients with non–small cell lung cancer and small cell lung cancer.

Edward B. Garon, MD, MS, discusses the mechanism of action of canakinumab.

The FDA has approved the liquid biopsy next-generation sequencing-based test FoundationOne Liquid CDx in companion with entrectinib for patients with non–small cell lung cancer with a ROS1 mutation in their tumor.

Dr Neal outlines second-line targeted treatment selection for the patient case, while Lauren Welch, MSN, NP-C, AOCNP, shares her experience with managing the adverse effects of mobocertinib in patients with EGFR exon 20-mutated mNSCLC and comments on potential strategies for treatment modification.

Dr Piotrowska and Lauren Welch offer insight into results interpretation and subsequent treatment decision-making for patients with mNSCLC who are found to harbor an EGFR exon 20 insertion mutation through biomarker testing.

The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.

Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.

According to Benjamin P. Levy, MD, clinicians can use the information currently available to best decide the treatment sequence of immunotherapy vs targeted agents in locally advanced non–small cell lung cancer.

In non–small cell lung cancer, EGFR mutations, MET exon 14 skipping mutations, and HER2 mutations are common mutation for which directed therapies are available.

Select racial groups have benefitted from important updates made to the USPSTF lung cancer screening guideline a year ago.

According to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.

In an early-intervention lung screening program, patients with lung cancer were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.

Dr Shiller emphasizes the heterogeneity between the various EGFR exon 20 mutations seen in patients with NSCLC, and describes strategies for effectively communicating actionable information about a patient’s mutation status to the clinicians receiving the reports.

In this companion article, Dr Luis Raez provides insights into effective management patients with extensive-stage small cell lung cancer who develop chemotherapy-induced myelosuppression.

Dr Neal discusses the design and outcomes of the CHRYSALIS study, investigating amivantamab for the treatment of EGFR exon 20-mutant advanced or metastatic lung cancer, and then briefly comments on a matched analysis of efficacy data on mobocertinib and amivantamab.

Two experts discuss the evolving treatment landscape for patients with non-small cell lung cancer (NSCLC) and reviews the role of molecular testing and discusses some of the challenges faced.

Data from patients with non–small cell lung cancer in the United States are adjustable to approximate overall survival in selected populations of Canadian patients

In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.

Data from the phase 3 PEARL study show that durvalumab does not induce statistically significant overall survival in patients with metastatic non–small cell lung cancer.

Closing out his discussion on the management of advanced non–small cell lung cancer, an expert oncologist provides his hopes for future evolutions in the treatment paradigm.

In light of clinical data and real-world experience, Jason Porter, MD, considers how he would best select patients with non–small cell lung cancer for IO therapy.

Jason Porter, MD, shares a brief review of the toxicity profile noted on EMPOWER-Lung3 and provides practical advice on how to monitor for and manage adverse events.

Expert perspective on the EMPOWER-Lung3 clinical trial, which combined cemiplimab with chemotherapy as frontline treatment for patients with advanced NSCLC.

Comprehensive insight on the first-line treatment armamentarium available to patients diagnosed with metastatic squamous cell non–small cell lung cancer.

Centering discussion on a patient scenario of metastatic squamous cell NSCLC, expert oncologist Jason Porter, MD, shares his initial impressions on the case.

During a Targeted Oncology case-based roundtable event, Patrick Forde, MBBCh, discussed the use of the regimen consisting of nivolumab, ipilimumab, and 2 cycles of chemotherapy for non–small cell lung cancer.

Findings from 3 studies show that treatment with plinabulin elicits efficacy and reduces the duration of severe neutropenia in patients with non–small cell lung cancer receiving docetaxel.

A safety review committee has approved the Acclaim-1 trial of ozeplasmid plus osimertinib in non–small cell lung cancer to move on to the third cohort of the study.

Dr Joel Neal reviews data from the pivotal clinical trial leading to the FDA approval of mobocertinib for EGFR exon 20-mutated advanced or metastatic lung cancers.

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.